Form 4: Revolution Medicines Exec Trades Shares Under 10b5-1 Plan

Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc., reported transactions involving the acquisition and disposition of company stock under a pre-arranged trading plan.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc., executed a series of stock transactions on June 11, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 12, 2026.
• Horn acquired 1,094 shares at an average price of $42.45 and 8,906 shares at an average price of $40.74.
• Concurrently, she disposed of a total of 8,400 shares across multiple transactions with a weighted average sale price ranging from $143.78 to $150.15.
• Following these transactions, Horn beneficially owns 158,222 shares of common stock.
• The filing also notes that 73,050 restricted stock units are included in her beneficial ownership, and 652 shares were acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions conducted under a pre-established plan, without providing new strategic or financial information.

Positives

• Acquisition of 1,094 shares at $42.45 and 8,906 shares at $40.74 indicates continued investment or compensation-related activity at lower price points.
• The use of a Rule 10b5-1 plan demonstrates proactive and compliant insider trading strategy, mitigating concerns about opportunistic trading.
• The acquisition of shares under the Employee Stock Purchase Plan suggests ongoing participation in employee benefit programs.

Negatives

• Significant disposition of 8,400 shares, even under a pre-arranged plan, could be interpreted negatively by the market, especially if it represents a substantial portion of holdings.
• The sale prices, ranging from $143.78 to $150.15, are considerably higher than the acquisition prices, indicating a profitable exit for a portion of the shares.

Risks

• The disposition of a significant number of shares, even under a 10b5-1 plan, may signal a lack of confidence in near-term price appreciation or a need for personal liquidity.
• The difference between acquisition and disposition prices highlights the potential for substantial gains, which could be a factor in future stock performance if such gains are realized broadly.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage their compensation and personal finances while adhering to regulatory requirements. The significant price difference between acquisitions and dispositions in this filing reflects the volatility often seen in this industry.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may lead to short-term market scrutiny or perception of reduced insider confidence, potentially impacting share price.
• Employees: The acquisition of shares through the Employee Stock Purchase Plan reinforces employee participation and potential alignment with company performance.
• Management: The transactions reflect the execution of pre-planned financial strategies by management, adhering to regulatory frameworks.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Options, Restricted Stock Units, Beneficial Ownership, Revolution Medicines, RVMD, Margaret A. Horn, Stock Transactions